These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 17011068)

  • 1. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
    Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
    Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
    Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
    Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
    Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
    Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
    Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
    Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
    Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
    Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
    Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
    J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.
    Schmittel A; Schulze K; Hütter G; Krebs P; Thiel E; Keilholz U
    Onkologie; 2004 Jun; 27(3):280-4. PubMed ID: 15249718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.
    Misumi Y; Okamoto H; Sasaki J; Masuda N; Ishii M; Shimokawa T; Hosomi Y; Okuma Y; Nagamata M; Ogura T; Kato T; Sata M; Otani S; Takakura A; Minato K; Miura Y; Yokoyama T; Takata S; Naoki K; Watanabe K
    BMC Cancer; 2017 May; 17(1):377. PubMed ID: 28549414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
    Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
    J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.
    Murata Y; Hirose T; Yamaoka T; Shirai T; Okuda K; Sugiyama T; Kusumoto S; Nakashima M; Ohmori T; Adachi M
    Eur J Cancer; 2011 Jun; 47(9):1336-42. PubMed ID: 21458256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer.
    Jeong HC; Lee SY; Lee SY; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
    Lung Cancer; 2006 Sep; 53(3):361-6. PubMed ID: 16846662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.
    Horn L; Zhao Z; Sandler A; Johnson D; Shyr Y; Wolff S; Devore RF; Laskin J
    Clin Lung Cancer; 2011 May; 12(3):161-5. PubMed ID: 21663858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group.
    Pectasides D; Fountzilas G; Rigopoulos A; Bountouroglou NG; Koutras A; Glotsos J; Onyenadum A; Makatsoris T; Kalofonos HP
    Anticancer Res; 2002; 22(6B):3501-6. PubMed ID: 12552946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.
    Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer.
    Park SH; Cho EK; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Lee JI; Choi SJ; Park J; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1009-14. PubMed ID: 18259751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
    Kinoshita A; Fukuda M; Soda H; Nagashima S; Fukuda M; Takatani H; Kuba M; Nakamura Y; Tsurutani J; Kohno S; Oka M;
    Br J Cancer; 2006 May; 94(9):1267-71. PubMed ID: 16622467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
    Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
    Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.